Sesen Bio Information

We are passionate in our commitment to save and improve the lives of patients. Sesen Bio is a late-stage company developing fusion protein medicines for the treatment of patients with cancer. In February 2021, the FDA accepted for filing the Company’s BLA for Vicineum™, a potential best-in-class treatment for non-muscle invasive bladder cancer.

Website	http://www.sesenbio.com
Ticker	EBIO
Revenue	$40 million
Funding	$50 million
Employees	36 (0 on RocketReach)
Founded	2010
Address	245 FIRST St. Ste. 1800, Cambridge, Massachusetts 02142, US
Phone	+1 617-871-9911
Fax	(617) 858-0911
Technologies	JavaScript , HTML , Google Analytics +27 more (view full list)
Industry	Biotechnology, Pharmaceuticals, Healthcare, Science and Engineering, Health Care, Drug Manufacturing & Research, Medical Device, Medical Testing & Clinical Laboratories
Web Rank	33 Million
Keywords	Cancer Treatment, Cancer Therapies, Oncology, Cancer Research, Pharmaceutical, Drug Development, Medicine Development, Biotechnology, Clinical Trials, Protein Therapeutics, Biopharma, Therapeutic Proteins, New Drugs, Fda Approval, Novel Therapeutics, Targeted Therapy, Immunotherapy, Health Technology
Competitors	Amgen, Genentech, Bristol Myers Squibb, Roche, Lilly India, Pfizer, AstraZeneca, Merck & Co., Inc., Bayer, Sanofi +66 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies
NAICS	NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 325412 Companies